Diagnostic microbiology could be turned on its head with the use of real-time PCR in the clinical setting.

The first merger of 2006 has created new opportunities in the hot field of theranostics. Ruth Beran talks with its architects about the merged company and its future plans.

Panbio's (ASX:PBO) US subsidiary Panbio Inc has been awarded almost US$100,000 (AUD$135,000) in funding from the US Deparment of Defence.

Melbourne-based health-management house HealthLinx has signed a collaboration agreement with US clinical proteomics company Bruker Daltonics to develop a multiplex, in vitro diagnostic (IVD) assay for ovarian cancer.

Eighteen years ago CSIRO biochemist Dr Robin Holliday first advanced the radical idea that that perfectly normal genes inactivated by hypermethylation played a role in the onset of cancer. Today, specific, sensitive tests for methylation are being developed which could play a role in early detection of cancer.

Medical diagnostics company Panbio (ASX:PBO) has been awarded a Queensland government grant towards the cost of developing its new R&D and manufacturing facility in Brisbane.

Agilent Technologies claims to have found a new way to detect genetically modified (GM) content in food products that allows rapid screening using the company's 2100 bioanalyser with its DNA 500 LabChip.